Literature DB >> 3839584

Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity.

J W Paxton, J L Jurlina.   

Abstract

Plasma amsacrine kinetics have been studied in rabbits after different doses (2.5-10 mg/kg) infused over 35 min. Amsacrine concentrations were measured by HPLC and plasma protein binding by equilibrium dialysis. All elimination curves were best fitted by a bi-exponential expression with a mean t 1/2 alpha of 0.56 h and t 1/2 beta of 2.47 h. At doses greater than 5 mg/kg, there appeared to be an overproportional increase in the area under the curve, suggesting non-linear kinetics. Comparison of pharmacokinetic parameters indicated a significant decrease in plasma Cl after the 10-mg/kg dose compared to the 5- and 2.5-mg/kg dose. Amsacrine was highly bound by plasma (96.8%) over the concentration range 1-100 mumol/l. It is concluded that the rabbit is an acceptable model for further studies of the pharmacokinetics of amsacrine and its analogues at doses less than or equal to 5 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3839584     DOI: 10.1159/000138097

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

1.  The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit.

Authors:  J W Paxton; S E Foote; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.

Authors:  J W Paxton; P C Evans; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.

Authors:  J W Paxton; J L Jurlina
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.